Sugi Predict

Sugi Predict / Compounds / SCHEMBL255602

SCHEMBL255602

SCHEMBL255602

CC(=O)O[C@@H](C(=O)O)[C@@H](OC(C)=O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.50
▸ TP53 P04637 2/20 0.41
▸ SLC1A3 P43003 1/20 0.40
▸ SLC1A2 P43004 1/20 0.40
▸ SLC1A1 P43005 1/20 0.40
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ ALOX15 P16050 1/20 0.38
▸ CHRM2 P08172 1/20 0.37
▸ CHRM4 P08173 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ TBXA2R P21731 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GALR3 O60755 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7092944 1.00 TSHR (0.50) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL13849512 1.00 TSHR (0.50) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL42203 1.00 TSHR (0.50) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL1442538 1.00 TSHR (0.50) TSHRTP53SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL9842020 0.97 TSHR (0.48) TSHRTP53SLC1A3SLC1A2SLC1A1
Water SCHEMBL28115835 0.97 TSHR (0.48) TSHRTP53SLC1A3SLC1A2SLC1A1
Ammonia Solution, Strong SCHEMBL1333562 0.97 TSHR (0.48) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL18857848 0.92 TSHR (0.43) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL28297278 0.92 TSHR (0.43) TSHRTP53SLC1A3SLC1A2SLC1A1
SCHEMBL8458943 0.87 TSHR (0.40) TSHRTP53SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504830-A Monetail key intermediate and resolution method thereof 菏泽皓元医药科技有限公司 2025-02-25 — — CN claimed
CN-112384493-A Process for the preparation of fused tricyclic gamma-amino acid derivatives and intermediates 四川海思科制药有限公司 2021-02-19 — — CN claimed
WO-2020029762-A1 PREPARATION METHOD FOR FUSED TRICYCLIC γ-AMINO ACID DERIVATIVE AND INTERMEDIATE THEREOF 四川海思科制药有限公司 2020-02-13 — — WO claimed
US-20170231966-A1 INHIBITION OF IL-2 PRODUCTION AYUMI PHARMACEUTICAL CORPORATION (JP) 2017-08-17 — — US claimed
US-9650351-B2 Inhibition of IL-2 production AYUMI PHARMACEUTICAL CORPORATION (JP) 2017-05-16 — — US claimed
EP-0420120-B1 Optically active benzyl alcohol compound and pharmaceutical composition HOKURIKU PHARMACEUTICAL (JP) 1994-08-31 — — EP claimed
EP-0420120-A2 Optically active benzyl alcohol compound and pharmaceutical composition HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-04-03 — — EP claimed
US-20260015355-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2026-01-15 — — US disclosed
US-20250340553-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2025-11-06 — — US disclosed
US-12448381-B1 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters BAYER AKTIENGESELLSCHAFT (DE) 2025-10-21 — — US disclosed
US-20250270204-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-HYDROXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXYLATE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2025-08-28 — — US disclosed
CN-119504830-A Monetail key intermediate and resolution method thereof 菏泽皓元医药科技有限公司 2025-02-25 — — CN disclosed
US-20240376103-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS BAYER AKTIENGESELLSCHAFT (DE) 2024-11-14 — — US disclosed
EP-0520320-A2 Tetrahydropyrrolo 1,2-a pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1992-12-30 — — EP disclosed
US-5144025-A PROCESS FOR THE RESOLUTION OF INTERMEDIATES USEFUL IN THE PREPARATION OF 1,5-BENZOTHIAZEPINES ZAMBON GROUP S.P.A. (IT) 1992-09-01 — — US disclosed
EP-0331943-B1 PHENOXYETHYLAMINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR EXHIBITING EXCELLENT ALPHA-1-BLOCKING ACTIVITY CONTAINING THE SAME Hokuriku Pharmaceutical Co.,Ltd (JP) 1992-06-17 — — EP disclosed
EP-0420120-A2 Optically active benzyl alcohol compound and pharmaceutical composition HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-04-03 — — EP disclosed
US-4971990-A HYPOTENSIVE AGENTS, DYSUREA HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1990-11-20 — — US disclosed
EP-0392543-A1 Process for the resolution of intermediates useful in the preparation of 1,5-benzothiazepines ZAMBON GROUP S.p.A. (IT) 1990-10-17 — — EP disclosed
EP-0331943-A1 Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same Hokuriku Pharmaceutical Co.,Ltd (JP) 1989-09-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270204-A1 PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-HYDROXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXYLATE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS MVD, CYP24A1, CYP4B1 TSHR 2129/4885TP53 1702/4885SLC1A3 2005/4885
US-20250340553-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS SRD5A1, NR4A1, SRD5A2 TSHR 1011/4885TP53 3176/4885SLC1A3 2501/4885
US-20260015355-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS NR3C2, SRD5A1, SRD5A2 TSHR 509/4885TP53 3367/4885SLC1A3 1844/4885
US-20240376103-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS SRD5A1, NR4A1, SRD5A2 TSHR 1011/4885TP53 3176/4885SLC1A3 2501/4885
US-12448381-B1 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters SRD5A1, NR4A1, SRD5A2 TSHR 1011/4885TP53 3176/4885SLC1A3 2501/4885
US-20170231966-A1 INHIBITION OF IL-2 PRODUCTION IL2, IL2RA, IL4 TSHR 1440/4885TP53 1187/4885SLC1A3 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.